HPV-specific immunotherapy: Key role for immunomodulators

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 2, 2014, Pages 265-279

  Van de Wall, Stephanie ^a   Nijman, Hans W ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adjuvant; Cervical cancer; HPV; Human papillomavirus; Immunomodulators; Immunotherapy; Vaccine

Indexed keywords

ADAPTIVE IMMUNITY; ANIMALS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84893517395     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152061402140128163306     Document Type: Review

References (132)

1. Parkin, D. M.; Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006, 24 (Suppl 3), S3/11-25.
2. Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 2006, 118, 3030-3044.
3. De Villiers, E. M.; Fauquet, C.; Broker, T. R.; Bernard, H. U.; Zur Hausen, H. Classification of papillomaviruses. Virology, 2004, 324, 17-27.
4. Schiffman, M.; Castle, P. E.; Jeronimo, J.; Rodriguez, A. C.; Wacholder, S. Human papillomavirus and cervical cancer. Lancet, 2007, 370, 890-907.
5. Snijders, P. J.; Steenbergen, R. D.; Heideman, D. A.; Meijer, C. J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol., 2006, 208, 152-164.
6. Cuzick, J.; Castanon, A.; Sasieni, P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br. J. Cancer, 2010, 102, 933-939.
7. Howley, P. M.; Munger, K.; Romanczuk, H.; Scheffner, M.; Huibregtse, J. M. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp., 1991, 22, 239-248.
8. Cronje, H. S. Screening for cervical cancer in developing countries. Int. J. Gynaecol. Obstet., 2004, 84, 101-108.
9. Schiller, J. T.; Lowy, D. R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol,. 2012, 10, 681-692.
10. Herzog, T. J. New approaches for the management of cervical cancer. Gynecol. Oncol., 2003, 90, S22-7.
11. Lin, K.; Roosinovich, E.; Ma, B.; Hung, C. F.; Wu, T. C. Therapeutic HPV DNA vaccines. Immunol. Res., 2010, 47, 86-112.
12. Zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer., 2002, 2, 342-350.
13. Su, J. H.; Wu, A.; Scotney, E.; Ma, B.; Monie, A.; Hung, C. F.; Wu, T. C. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs, 2010, 24, 109-129.
14. Berzofsky, J. A.; Terabe, M.; Wood, L. V. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin. Oncol., 2012, 39, 348-357.
15. Coffman, R. L.; Sher, A.; Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity, 2010, 33, 492-503.
16. Alving, C. R.; Peachman, K. K.; Rao, M.; Reed, S. G. Adjuvants for human vaccines. Curr. Opin. Immunol,. 2012, 24, 310-315.
17. Stewart, T. J.; Smyth, M. J. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev., 2011, 30, 125-140.
18. Lin, K. Y.; Guarnieri, F. G.; Staveley-O'Carroll, K. F.; Levitsky, H. I.; August, J. T.; Pardoll, D. M.; Wu, T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 1996, 56, 21-26.
19. Schulz, O.; Diebold, S. S.; Chen, M.; Naslund, T. I.; Nolte, M. A.; Alexopoulou, L.; Azuma, Y. T.; Flavell, R. A.; Liljestrom, P.; Reis e Sousa, C. Toll-like receptor 3 promotes cross-priming to virusinfected cells. Nature, 2005, 433, 887-892.
20. Crespo, M. I.; Zacca, E. R.; Nunez, N. G.; Ranocchia, R. P.; Maccioni, M.; Maletto, B. A.; Pistoresi-Palencia, M. C.; Moron, G. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J. Immunol., 2013, 190, 948-960.
21. Zaks, K.; Jordan, M.; Guth, A.; Sellins, K.; Kedl, R.; Izzo, A.; Bosio, C.; Dow, S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol., 2006, 176, 7335-7345.
22. Daubenberger, C. A. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr. Opin. Mol. Ther., 2007, 9, 45-52.
23. Chen, X. Z.; Mao, X. H.; Zhu, K. J.; Jin, N.; Ye, J.; Cen, J. P.; Zhou, Q.; Cheng, H. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch. Dermatol. Res., 2010, 302, 57-65.
24. Daud, I. I.; Scott, M. E.; Ma, Y.; Shiboski, S.; Farhat, S.; Moscicki, A. B. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int. J. Cancer, 2011, 128, 879-886.
25. Yu, L.; Wang, L.; Li, M.; Zhong, J.; Wang, Z.; Chen, S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol. Immunother., 2010, 59, 1021-1028.
26. Zom, G. G.; Khan, S.; Filippov, D. V.; Ossendorp, F. TLR ligandpeptide conjugate vaccines: toward clinical application. Adv. Immunol., 2012, 114, 177-201.
27. Geller, M. A.; Cooley, S.; Argenta, P. A.; Downs, L. S.; Carson, L. F.; Judson, P. L.; Ghebre, R.; Weigel, B.; Panoskaltsis-Mortari, A.; Curtsinger, J.; Miller, J. S. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol. Immunother., 2010, 59, 1877-1884.
28. Dummer, R.; Hauschild, A.; Becker, J. C.; Grob, J. J.; Schadendorf, D.; Tebbs, V.; Skalsky, J.; Kaehler, K. C.; Moosbauer, S.; Clark, R.; Meng, T. C.; Urosevic, M. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res., 2008, 14, 856-864.
29. Halperin, S. A.; Ward, B.; Cooper, C.; Predy, G.; Diaz-Mitoma, F.; Dionne, M.; Embree, J.; McGeer, A.; Zickler, P.; Moltz, K. H.; Martz, R.; Meyer, I.; McNeil, S.; Langley, J. M.; Martins, E.; Heyward, W. L.; Martin, J. T. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine, 2012, 30, 2556-2563.
30. Sablan, B. P.; Kim, D. J.; Barzaga, N. G.; Chow, W. C.; Cho, M.; Ahn, S. H.; Hwang, S. G.; Lee, J. H.; Namini, H.; Heyward, W. L. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30, 2689-2696.
31. Wallecha, A.; Wood, L.; Pan, Z.; Maciag, P. C.; Shahabi, V.; Paterson, Y. Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clin. Vaccine Immunol., 2013, 20, 77-84.
32. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124, 783-801.
33. Alexopoulou, L.; Holt, A. C.; Medzhitov, R.; Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 2001, 413, 732-738.
34. CSID: 143099. Available at: http://www. chemspider. com/Chemical-Structure. 143099 [Accessed July 20, 2013].
35. Boullart, A. C.; Aarntzen, E. H.; Verdijk, P.; Jacobs, J. F.; Schuurhuis, D. H.; Benitez-Ribas, D.; Schreibelt, G.; van de Rakt, M. W.; Scharenborg, N. M.; de Boer, A.; Kramer, M.; Figdor, C. G.; Punt, C. J.; Adema, G. J.; de Vries, I. J. Maturation of monocytederived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother., 2008, 57, 1589-1597.
36. Navabi, H.; Jasani, B.; Reece, A.; Clayton, A.; Tabi, Z.; Donninger, C.; Mason, M.; Adams, M. A clinical grade poly I: C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine, 2009, 27, 107-115.
37. Schulz, O.; Reis e Sousa, C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology, 2002, 107, 183-189.
38. Wick, D. A.; Martin, S. D.; Nelson, B. H.; Webb, J. R. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I: C). Vaccine, 2011, 29, 984-993.
39. Barrios, K.; Celis, E. TriVax-HPV: An improved peptide-based therapeutic vaccination strategy against human papillomavirusinduced cancers. Cancer Immunol. Immunother., 2012, 61, 1307-1317.
40. Chen, S.; Ou, R.; Tang, J.; Deng, X.; Wu, Y.; van Velkinburgh, J. C.; Ni, B.; Xu, Y. Enhanced antitumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I: C) and oxygen-regulated protein 150. Cancer. Epidemiol., 2013, 37, 172-178.
41. Wu, C. Y.; Monie, A.; Pang, X.; Hung, C. F.; Wu, T. C. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J. Biomed. Sci., 2010, 17, 88-0127-17-88.
42. Smith, K. A.; Meisenburg, B. L.; Tam, V. L.; Pagarigan, R. R.; Wong, R.; Joea, D. K.; Lantzy, L.; Carrillo, M. A.; Gross, T. M.; Malyankar, U. M.; Chiang, C. S.; Da Silva, D. M.; Kundig, T. M.; Kast, W. M.; Qiu, Z.; Bot, A. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin. Cancer Res., 2009, 15, 6167-6176.
43. Wick, D. A.; Webb, J. R. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine, 2011, 29, 7857-7866.
44. Robinson, R. A.; DeVita, V. T.; Levy, H. B.; Baron, S.; Hubbard, S. P.; Levine, A. S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl. Cancer Inst. 1976, 57, 599-602.
45. Stahl-Hennig, C.; Eisenblatter, M.; Jasny, E.; Rzehak, T.; Tenner-Racz, K.; Trumpfheller, C.; Salazar, A. M.; Uberla, K.; Nieto, K.; Kleinschmidt, J.; Schulte, R.; Gissmann, L.; Muller, M.; Sacher, A.; Racz, P.; Steinman, R. M.; Uguccioni, M.; Ignatius, R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog., 2009, 5, e1000373.
46. Hansen, J.; Lindenstrom, T.; Lindberg-Levin, J.; Aagaard, C.; Andersen, P.; Agger, E. M. CAF05: Cationic liposomes that incorporate synthetic cord factor and poly(I: C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunol. Immunother., 2012, 61, 893-903.
47. Didierlaurent, A. M.; Morel, S.; Lockman, L.; Giannini, S. L.; Bisteau, M.; Carlsen, H.; Kielland, A.; Vosters, O.; Vanderheyde, N.; Schiavetti, F.; Larocque, D.; Van Mechelen, M.; Garcon, N. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol., 2009, 183, 6186-6197.
48. NCBI. Chemicals & Bioassays. PubChem. Carrageenan-Compound Summary. Available at: http://pubchem. ncbi. nlm. nih. gov/summary/summary. cgi?cid=11966249&loc=ec_rcs#itabs-2d [Accessed July 20, 2013].
49. Zhang, Y. Q.; Tsai, Y. C.; Monie, A.; Hung, C. F.; Wu, T. C. Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine, 2010, 28, 5212-5219.
50. Mansilla, C.; Berraondo, P.; Durantez, M.; Martinez, M.; Casares, N.; Arribillaga, L.; Rudilla, F.; Fioravanti, J.; Lozano, T.; Villanueva, L.; Sarobe, P.; Borras, F.; Leclerc, C.; Prieto, J.; Lasarte, J. J. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int. J. Cancer, 2012, 131, 641-651.
51. NCBI. Chemicals & Bioassays. PubChem. Imiquimod-Compound Summary. Available at: http://pubchem. ncbi. nlm. nih. gov/summary/summary. cgi?cid=57469 [Accessed July 20, 2013].
52. NCBI. Chemicals & Bioassays. PubChem. Resiquimod-Compound Summary. http://pubchem. ncbi. nlm. nih. gov/summary/summary. cgi? cid=159603 [Accessed July 20, 2013].
53. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol., 2002, 168, 4531-4537.
54. Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper, W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. S.; Vasilakos, J. P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol., 2005, 174, 1259-1268.
55. Fahey, L. M.; Raff, A. B.; Da Silva, D. M.; Kast, W. M. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J. Immunol., 2009, 182, 2919-2928.
56. Beutner, K. R.; Spruance, S. L.; Hougham, A. J.; Fox, T. L.; Owens, M. L.; Douglas, J. M., Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J. Am. Acad. Dermatol., 1998, 38, 230-239.
57. Lin, C. T.; Qiu, J. T.; Wang, C. J.; Chang, S. D.; Tang, Y. H.; Wu, P. J.; Jung, S. M.; Huang, C. C.; Chou, H. H.; Jao, M. S.; Lai, C. H. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. Taiwan. J. Obstet. Gynecol., 2012, 51, 533-538.
58. Terlou, A.; van Seters, M.; Kleinjan, A.; Heijmans-Antonissen, C.; Santegoets, L. A.; Beckmann, I.; Van Beurden, M.; Helmerhorst, T. J.; Blok, L. J. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int. J. Cancer, 2010, 127, 2831-2840.
59. Daayana, S.; Elkord, E.; Winters, U.; Pawlita, M.; Roden, R.; Stern, P. L.; Kitchener, H. C. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer, 2010, 102, 1129-1136.
60. NCI. Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia. http://clinicaltrials. gov/ct2/show/NCT00788164 (Accessed Feb 10, 2013).
61. Adams, S.; O'Neill, D. W.; Nonaka, D.; Hardin, E.; Chiriboga, L.; Siu, K.; Cruz, C. M.; Angiulli, A.; Angiulli, F.; Ritter, E.; Holman, R. M.; Shapiro, R. L.; Berman, R. S.; Berner, N.; Shao, Y.; Manches, O.; Pan, L.; Venhaus, R. R.; Hoffman, E. W.; Jungbluth, A.; Gnjatic, S.; Old, L.; Pavlick, A. C.; Bhardwaj, N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol., 2008, 181, 776-784.
62. Feyerabend, S.; Stevanovic, S.; Gouttefangeas, C.; Wernet, D.; Hennenlotter, J.; Bedke, J.; Dietz, K.; Pascolo, S.; Kuczyk, M.; Rammensee, H. G.; Stenzl, A. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.
63. Steinhagen, F.; Kinjo, T.; Bode, C.; Klinman, D. M. TLR-based immune adjuvants. Vaccine, 2011, 29, 3341-3355.
64. Chuang, C. M.; Monie, A.; Hung, C. F.; Wu, T. C. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J. Biomed. Sci., 2010, 17, 32.
65. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature, 2000, 408, 740-745.
66. Fourcade, J.; Kudela, P.; Andrade Filho, P. A.; Janjic, B.; Land, S. R.; Sander, C.; Krieg, A.; Donnenberg, A.; Shen, H.; Kirkwood, J. M.; Zarour, H. M. Immunization with analog peptide in combination with CpG and montanide expands tumor antigenspecific CD8+ T cells in melanoma patients. J. Immunother., 2008, 31, 781-791.
67. Karbach, J.; Gnjatic, S.; Bender, A.; Neumann, A.; Weidmann, E.; Yuan, J.; Ferrara, C. A.; Hoffmann, E.; Old, L. J.; Altorki, N. K.; Jager, E. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer, 2010, 126, 909-918.
68. Valmori, D.; Souleimanian, N. E.; Tosello, V.; Bhardwaj, N.; Adams, S.; O'Neill, D.; Pavlick, A.; Escalon, J. B.; Cruz, C. M.; Angiulli, A.; Angiulli, F.; Mears, G.; Vogel, S. M.; Pan, L.; Jungbluth, A. A.; Hoffmann, E. W.; Venhaus, R.; Ritter, G.; Old, L. J.; Ayyoub, M. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 8947-8952.
69. Karbach, J.; Neumann, A.; Atmaca, A.; Wahle, C.; Brand, K.; von Boehmer, L.; Knuth, A.; Bender, A.; Ritter, G.; Old, L. J.; Jager, E. Efficient in vivo priming by vaccination with recombinant NYESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res., 2011, 17, 861-870.
70. Hasan, U. A.; Bates, E.; Takeshita, F.; Biliato, A.; Accardi, R.; Bouvard, V.; Mansour, M.; Vincent, I.; Gissmann, L.; Iftner, T.; Sideri, M.; Stubenrauch, F.; Tommasino, M. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol., 2007, 178, 3186-3197.
71. Smahel, M.; Polakova, I.; Sobotkova, E.; Vajdova, E. Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin. Dev. Immunol., 2011, 2011, 176759.
72. Ohlschlager, P.; Spies, E.; Alvarez, G.; Quetting, M.; Groettrup, M. The combination of TLR-9 adjuvantation and electroporationmediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int. J. Cancer, 2011, 128, 473-481.
73. Pokorna, D.; Polakova, I.; Kindlova, M.; Duskova, M.; Ludvikova, V.; Gabriel, P.; Kutinova, L.; Muller, M.; Smahel, M. Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine, 2009, 27, 3519-3529.
74. Kang, T. H.; Monie, A.; Wu, L. S.; Pang, X.; Hung, C. F.; Wu, T. C. Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine, 2011, 29, 1082-1089.
75. Domingos-Pereira, S.; Decrausaz, L.; Derre, L.; Bobst, M.; Romero, P.; Schiller, J. T.; Jichlinski, P.; Nardelli-Haefliger, D. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol., 2013, 6, 393-404.
76. Cerutti, M. L.; Alonso, L. G.; Tatti, S.; De Prat-Gay, G. Longlasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model. Int. J. Cancer, 2012, 130, 1813-1820.
77. Portielje, J. E.; Gratama, J. W.; van Ojik, H. H.; Stoter, G.; Kruit, W. H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother., 2003, 52, 133-144.
78. Nicholls, E. F.; Madera, L.; Hancock, R. E. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. N. Y. Acad. Sci., 2010, 1213, 46-61.
79. Brun, J. L.; Dalstein, V.; Leveque, J.; Mathevet, P.; Raulic, P.; Baldauf, J. J.; Scholl, S.; Huynh, B.; Douvier, S.; Riethmuller, D.; Clavel, C.; Birembaut, P.; Calenda, V.; Baudin, M.; Bory, J. P. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol., 2011, 204, e1-e8.
80. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 3539-3543.
81. Small, E. J.; Schellhammer, P. F.; Higano, C. S.; Redfern, C. H.; Nemunaitis, J. J.; Valone, F. H.; Verjee, S. S.; Jones, L. A.; Hershberg, R. M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol., 2006, 24, 3089-3094.
82. Schwartzentruber, D. J.; Lawson, D.; Richards, J.; Conry, R. M.; Miller, D.; Triesman, J.; Gailani, F.; Riley, L. B.; Vena, D.; Hwu, P. A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol., 2009, 27, CRA9011.
83. Tang, J.; Yin, R.; Tian, Y.; Huang, Z.; Shi, J.; Fu, X.; Wang, L.; Wu, Y.; Hao, F.; Ni, B. A novel self-assembled nanoparticle vaccine with HIV-1 Tat(4)(9)(-)(5)(7)/HPV16 E7(4)(9)(-)(5)(7) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8(+) T cell-dependent antitumor immunity in mice. Vaccine, 2012, 30, 1071-1082.
84. Lakatosova-Andelova, M.; Jinoch, P.; Duskova, M.; Marinov, I.; Vonka, V. Live cell vaccines expressing B7. 1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells. Int. J. Oncol., 2008, 32, 265-271.
85. Zurkova, K.; Babiarova, K.; Hainz, P.; Krystofova, J.; Kutinova, L.; Otahal, P.; Nemeckova, S. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol. Rep., 2009, 21, 1335-1343.
86. Sin, J. I. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. Immunology, 2009, 128, e707-17.
87. Riezebos-Brilman, A.; Regts, J.; Chen, M.; Wilschut, J.; Daemen, T. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine, 2009, 27, 701-707.
88. Mikyskova, R.; Indrova, M.; Simova, J.; Bieblova, J.; Bubenik, J.; Reinis, M. Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncol. Rep., 2011, 25, 1683-1689.
89. Ohlschlager, P.; Quetting, M.; Alvarez, G.; Durst, M.; Gissmann, L.; Kaufmann, A. M. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int. J. Cancer, 2009, 125, 189-198.
90. Mohit, E.; Bolhassani, A.; Zahedifard, F.; Seyed, N.; Eslamifar, A.; Taghikhani, M.; Samimi-Rad, K.; Rafati, S. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol. Immunol., 2013, 53, 149-160.
91. Kang, T. H.; Kim, K. W.; Bae, H. C.; Seong, S. Y.; Kim, T. W. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int. J. Cancer, 2011, 128, 702-714.
92. Kang, T. H.; Bae, H. C.; Kim, S. H.; Seo, S. H.; Son, S. W.; Choi, E. Y.; Seong, S. Y.; Kim, T. W. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. J. Gene Med., 2009, 11, 889-898.
93. Juarez, V.; Pasolli, H. A.; Hellwig, A.; Garbi, N.; Arregui, A. C. Virus-like particles harboring CCL19, IL-2 and HPV16 E7 elicit protective T cell responses in HLA-A2 transgenic mice. Open Virol. J., 2012, 6, 270-276.
94. Kim, Y. S.; Kim, Y. J.; Lee, J. M.; Han, S. H.; Ko, H. J.; Park, H. J.; Pereboev, A.; Nguyen, H. H.; Kang, C. Y. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Hum. Gene Ther., 2010, 21, 1697-1706.
95. Sharma, R. K.; Srivastava, A. K.; Yolcu, E. S.; MacLeod, K. J.; Schabowsky, R. H.; Madireddi, S.; Shirwan, H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine, 2010, 28, 5794-5802.
96. Sharma, R. K.; Elpek, K. G.; Yolcu, E. S.; Schabowsky, R.; Zhao, H.; Bandura-Morgan, L.; Shirwan, H. Costimulation as a platform for the development of vaccines: A peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res., 2009, 69, 4319-4326.
97. Taguchi, A.; Kawana, K.; Yokoyama, T.; Adachi, K.; Yamashita, A.; Tomio, K.; Kojima, S.; Oda, K.; Fujii, T.; Kozuma, S. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine, 2012, 30, 5368-5372.
98. CSID: 10196541. Available at: http://www. chemspider. com/Chemical-Structure. 10196541 [Accessed July 20, 2013].
99. Yan, W.; Chen, W. C.; Liu, Z.; Huang, L. Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine, 2010, 52, 238-244.
100. CSID: 2104816. Available at: http://www. chemspider. com/Chemical-Structure. 2104816 [Accessed July 20, 2013].
101. Kim, D.; Hung, C. F.; Wu, T. C.; Park, Y. M. DNA vaccine with alpha-galactosylceramide at prime phase enhances antitumor immunity after boosting with antigen-expressing dendritic cells. Vaccine, 2010, 28, 7297-7305.
102. Ding, Y.; Seow, S. V.; Huang, C. H.; Liew, L. M.; Lim, Y. C.; Kuo, I. C.; Chua, K. Y. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology, 2009, 128, e881; e894.
103. Karanam, B.; Gambhira, R.; Peng, S.; Jagu, S.; Kim, D. J.; Ketner, G. W.; Stern, P. L.; Adams, R. J.; Roden, R. B. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine, 2009, 27, 1040-1049.
104. Kenter, G. G.; Welters, M. J.; Valentijn, A. R.; Lowik, M. J.; Berends-van Der Meer, D. M.; Vloon, A P.; Essahsah, F.; Fathers, L. M.; Offringa, R.; Drijfhout, J. W.; Wafelman, A. R.; Oostendorp, J.; Fleuren, G. J.; Van der Burg, S. H.; Melief, C. J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med., 2009, 361, 1838-1847.
105. Welters, M. J.; Kenter, G. G.; De Vos van Steenwijk, P. J.; Lowik, M. J.; Berends-van der Meer, D. M.; Essahsah, F.; Stynenbosch, L. F.; Vloon, A. P.; Ramwadhdoebe, T. H.; Piersma, S. J.; van der Hulst, J. M.; Valentijn, A. R.; Fathers, L. M.; Drijfhout, J. W.; Franken, K. L.; Oostendorp, J.; Fleuren, G. J.; Melief, C. J.; van der Burg, S. H. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 11895-11899.
106. Visser, J.; Nijman, H. W.; Hoogenboom, B. N.; Jager, P.; van Baarle, D.; Schuuring, E.; Abdulahad, W.; Miedema, F.; Van der Zee, A. G.; Daemen, T. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin. Exp. Immunol., 2007, 150, 199-209.
107. Hoffmann, C.; Stanke, J.; Kaufmann, A. M.; Loddenkemper, C.; Schneider, A.; Cichon, G. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. J. Immunother., 2010, 33, 136-145.
108. Chuang, C. M.; Hoory, T.; Monie, A.; Wu, A.; Wang, M. C.; Hung, C. F. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine, 2009, 27, 684-689.
109. Walczak, M.; Regts, J.; Van Oosterhout, A. J.; Boon, L.; Wilschut, J.; Nijman, H. W.; Daemen, T. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther., 2011, 16, 207-218.
110. Kobayashi, A.; Weinberg, V.; Darragh, T.; Smith-McCune, K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol., 2008, 1, 412-420.
111. Choi, I.; Hwang, W.; Jung, K.; Jean, Y. Enhancement of DC vaccine efficacy via regulation of interleukin-6 receptor signaling. J. Immunol., 2011, 186, 66.
112. Vicari, A. P.; Trinchieri, G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol. Rev., 2004, 202, 223-236.
113. Kim, J. H.; Kang, T. H.; Noh, K. H.; Bae, H. C.; Ahn, Y. H.; Lee, Y. H.; Choi, E. Y.; Chun, K. H.; Lee, S. J.; Kim, T. W. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin. Exp. Immunol., 2011, 165, 180-189.
114. Kim, S.; Buchlis, G.; Fridlender, Z. G.; Sun, J.; Kapoor, V.; Cheng, G.; Haas, A.; Cheung, H. K.; Zhang, X.; Corbley, M.; Kaiser, L. R.; Ling, L.; Albelda, S. M. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res., 2008, 68, 10247-10256.
115. Zurkova, K.; Chlanda, P.; Samkova, Z.; Babiarova, K.; Kutinova, L.; Krystofova, J.; Hainz, P.; Nemeckova, S. Expression of soluble TGF-(beta) receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors. Neoplasma, 2011, 58, 181-188.
116. Conti, I.; Rollins, B. J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol., 2004, 14, 149-154.
117. Fridlender, Z. G.; Buchlis, G.; Kapoor, V.; Cheng, G.; Sun, J.; Singhal, S.; Crisanti, M. C.; Wang, L. C.; Heitjan, D.; Snyder, L. A.; Albelda, S. M. CCL2 blockade augments cancer immunotherapy. Cancer Res., 2010, 70, 109-118.
118. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol., 2003, 21, 305-334.
119. Linsley, P. S.; Ledbetter, J. A. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol., 1993, 11, 191-212.
120. Persson, J.; Beyer, I.; Yumul, R.; Li, Z.; Kiem, H. P.; Roffler, S.; Lieber, A. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PLoS One, 2011, 6, e22303.
121. Zheng, Y.; Zhang, Y.; Ma, Y.; Wan, J.; Shi, C.; Huang, L. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. J. Microbiol., 2008, 46, 728-736.
122. Liu, Y.; Tuve, S.; Persson, J.; Beyer, I.; Yumul, R.; Li, Z. Y.; Tragoolpua, K.; Hellstrom, K. E.; Roffler, S.; Lieber, A. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther., 2011, 18, 407-418.
123. Karim, R.; Jordanova, E. S.; Piersma, S. J.; Kenter, G. G.; Chen, L.; Boer, J. M.; Melief, C. J.; van der Burg, S. H. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res., 2009, 15, 6341-6347.
124. Song, M. Y.; Park, S. H.; Nam, H. J.; Choi, D. H.; Sung, Y. C. Enhancement of vaccine-induced primary and memory CD8(+) Tcell responses by soluble PD-1. J. Immunother., 2011, 34, 297-306.
125. Brahmer, J. R.; Tykodi, S. S.; Chow, L. Q.; Hwu, W. J.; Topalian, S. L.; Hwu, P.; Drake, C. G.; Camacho, L. H.; Kauh, J.; Odunsi, K.; Pitot, H. C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T. M.; Alaparthy, S.; Grosso, J. F.; Korman, A. J.; Parker, S. M.; Agrawal, S.; Goldberg, S. M.; Pardoll, D. M.; Gupta, A.; Wigginton, J. M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366, 2455-2465.
126. Brahmer, J. R.; Drake, C. G.; Wollner, I.; Powderly, J. D.; Picus, J.; Sharfman, W. H.; Stankevich, E.; Pons, A.; Salay, T. M.; McMiller, T. L.; Gilson, M. M.; Wang, C.; Selby, M.; Taube, J. M.; Anders, R.; Chen, L.; Korman, A. J.; Pardoll, D. M.; Lowy, I.; Topalian, S. L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol., 2010, 28, 3167-3175.
127. Diniz, M. O.; Lasaro, M. O.; Ertl, H. C.; Ferreira, L. C. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin. Vaccine Immunol., 2010, 17, 1576-1583.
128. Diniz, M.; Ferreira, L. C. S. IL-2 expression enhances the antitumor effects of a DNA vaccine encoding HPV-16 E7 oncoprotein genetically fused with the HSV-1 gD protein. Immunology, 2012, 137, 713-714.
129. Kanodia, S.; Da Silva, D. M.; Karamanukyan, T.; Bogaert, L.; Fu, Y. X.; Kast, W. M. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res., 2010, 70, 3955-3964.
130. Tseng, C. W.; Monie, A.; Trimble, C.; Alvarez, R. D.; Huh, W. K.; Buchsbaum, D. J.; Straughn, J. M., Jr; Wang, M. C.; Yagita, H.; Hung, C. F.; Wu, T. C. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. Vaccine, 2008, 26, 4314-4319.
131. Thompson, J. M.; Whitmore, A. C.; Staats, H. C.; Johnston, R. E. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine, 2008, 26(33), 4267-4275.
132. Geall, A. J.; Verma, A.; Otten, G. R.; Shaw, C. A.; Hekele, A.; Banerjee, K; Cu, Y.; Beard, C. W.; Brito, L. A.; Krucher, T.; O'Hagan, D. T.; Singh, M.; Mason, P. W.; Valiante, N. M.; Dormitzer, P. R.; Barnett, S. W.; Rappuoli, R. Ulmer, J. B.; Mandl, C. W. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA, 2008, 109(36), 14604-14609.